Triomab® Platform Candidates
Oncology (specifics undisclosed)
Clinical Stage (Phase unspecified)Active
Key Facts
Indication
Oncology (specifics undisclosed)
Phase
Clinical Stage (Phase unspecified)
Status
Active
Company
About Lindis Biotech
Lindis Biotech is a German, privately-held biotech founded in 2018, advancing its proprietary Triomab® bispecific antibody platform. The platform generates trifunctional antibodies that engage T-cells and accessory immune cells (like macrophages and NK cells) against tumors, aiming for a potent, multi-mechanistic attack with potential vaccination-like effects. As a clinical-stage company, it is pre-revenue and is actively seeking licensing and co-development partnerships to advance its pipeline.
View full company profileTherapeutic Areas
Other Oncology (specifics undisclosed) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Polymer-Drug Conjugate(s) | Nemucore Medical Innovations | Pre-clinical |
| Innovation Portfolio (505(b)(2)) | 6S Pharma | Pre-clinical |